BABOON OPSONOKINE VACCINE STUDY

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 一种新的免疫系统刺激剂，调理素，在小鼠模型中诱导针对癌症靶标和感染性疾病靶标（肝炎B病毒，HBV）的强烈免疫细胞应答（杀伤细胞应答）方面显示出很大的前景。调理素由一种蛋白质组成，通常参与体内激活和招募参与向免疫系统呈递靶标的细胞（所谓的抗原呈递细胞，APC）。这种蛋白质，人GMCSF（粒细胞单核细胞集落刺激因子），与流感病毒分子（GM-CSF-HA）相连。GM-CSF-HA与唾液酸结合，唾液酸存在于几乎所有哺乳动物细胞上，并允许现在的“粘性”分子结合并停留在注射部位，从而防止其扩散。我们将使用HBV靶蛋白HBsAg（B型肝炎表面抗原）与两种不同浓度的调理因子混合来评估HBV疫苗。我们将研究狒狒中抗HBsAg细胞毒性（杀伤）T细胞应答和B细胞抗体应答的诱导。这将通过在第0天和第28天首先免疫动物并在接下来的14周内收集血样以确定免疫应答来完成。现有的HBV疫苗仅限于保护个体免受感染，但对已感染的患者不起治疗作用。这里的目标是确定我们是否可以产生适当的免疫反应，最终导致对已经感染传染病病毒的个体的治疗。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A new immune system stimulator, Opsonokine, has shown great promise in inducing strong immune cell responses (killer cell responses) against both cancer targets and infectious disease targets (Hepatitis B Virus , HBV) in mouse models. The Opsonokine consists of a protein normally involved in the body to activate and recruit cells involved in presenting targets to the immune system (so called Antigen Presenting Cells, APC). This protein, human GMCSF (granulocyte monocyte - colony stimulating factor), is linked to the influenza molecule (GM-CSF-HA). The GM-CSF-HA binds to sialic acid, which is present on virtually all mammalian cells and allows the now "sticky" molecule to bind and stay at the injection site which prevents it from diffusing away. We will evaluate an HBV vaccine, using the HBV target protein HBsAg (Hepatitis B surface antigen) mixed with two different concentrations of the Opsonokine. We will study the induction in the baboon of both an anti-HBsAg cytotoxic (killer) T-cell response and B-cell antibody response. This will be done by first immunizing the animals at 0 and 28 days and for the next 14 weeks collect blood samples to determine the immune response. The existing vaccines for HBV are limited to protecting individuals from infection but do not work as therapy in already infected patients. The goal here is to determine if we can generate a proper immune response that ultimately results in a therapy for individuals already infected with a infectious disease virus.